Skip to Main content Skip to Navigation
Journal articles

Clinical pharmacology of anti-angiogenic drugs in oncology

Abstract : Abnormal vasculature proliferation is one of the so-called hallmarks of cancer. Angiogenesis inhibitor therapies are one of the major breakthroughs in cancer treatment in the last two decades. Two types of anti-angiogenics have been approved: monoclonal antibodies and derivatives, which are injected and target the extracellular part of a receptor, and protein kinase inhibitors, which are orally taken small molecules targeting the intra-cellular Adenosine Triphosphate –pocket of different kinases. They have become an important part of some tumors' treatment, both in monotherapy or in combination. In this review, we discuss the key pharmacological concepts and the major pitfalls of anti-angiogenic prescriptions. We also review the pharmacokinetic and pharmacody-namics profile of all approved anti-angiogenic protein kinase inhibitors and the potential role of surrogate markers and of therapeutic drug monitoring.
Complete list of metadata

Cited literature [202 references]  Display  Hide  Download

https://hal.sorbonne-universite.fr/hal-01662030
Contributor : Gestionnaire Hal-Upmc <>
Submitted on : Tuesday, December 12, 2017 - 4:04:05 PM
Last modification on : Thursday, December 10, 2020 - 3:44:06 AM

File

Pharmacology of AA - 2017_sans...
Files produced by the author(s)

Identifiers

Citation

P. Gougis, J. Wassermann, J.P. Spano, N. Keynan, C. Funck-Brentano, et al.. Clinical pharmacology of anti-angiogenic drugs in oncology. Critical Reviews in Oncology/Hematology, Elsevier, 2017, 119, pp.75-93. ⟨10.1016/j.critrevonc.2017.08.010⟩. ⟨hal-01662030⟩

Share

Metrics

Record views

198

Files downloads

544